Form 4: Outset Medical Director Patrick Hackett Reports Acquisition of 8,983 Shares in RSU Grant

Outset Medical, Inc. Director Patrick T. Hackett reported the acquisition of 8,983 shares of common stock through a Restricted Stock Unit (RSU) grant, increasing his total beneficial ownership to 95,172 direct shares.

Summary

• Patrick T. Hackett, a Director of Outset Medical, Inc. (OM), acquired 8,983 shares of common stock on June 2, 2025.
• This acquisition was an RSU grant with a reported price of $0.0.
• Following this transaction, Mr. Hackett directly beneficially owns 95,172 shares of common stock.
• He also indirectly owns 83,333 shares through the GST Trust and 41,666 shares through the Hackett Family Fund.
• The shares underlying these RSUs will vest 100% upon the earlier of the one-year anniversary of the grant date or the date of the Issuer's next Annual Meeting of Stockholders.
• All reported share numbers have been adjusted to reflect the 1-for-15 reverse stock split effected by Outset Medical on March 20, 2025.

Sentiment

Score: 7

Explanation: The RSU grant to a director is a positive signal of continued alignment between management/board and shareholder interests. It's a standard compensation practice, not indicative of extraordinary news, hence a moderately positive score.

Positives

• The acquisition of 8,983 shares via an RSU grant aligns the director's interests with those of shareholders, as the value of these shares is tied to the company's stock performance.
• The vesting schedule provides an incentive for long-term commitment and performance from the director.

Future Outlook

The 8,983 Restricted Stock Units granted to Director Patrick T. Hackett are scheduled to vest 100% upon the earlier of the one-year anniversary of the grant date (June 2, 2026) or the date of the Issuer's next Annual Meeting of Stockholders, indicating future equity compensation realization.

Industry Context

This Form 4 filing reports a standard equity compensation grant to a director, a common practice across industries to align executive and board interests with shareholder value. Such grants are typical in the medical device and healthcare technology sectors, where long-term innovation and market penetration are key.

Comparison to Industry Standards

• Equity grants, particularly RSUs, are a standard component of director compensation packages in publicly traded companies, including those in the medical technology sector.
• The specific size of the grant (8,983 shares) and the vesting schedule (one-year anniversary or next annual meeting) are typical for aligning director incentives with company performance and retention, though specific comparisons would require detailed compensation data from peer companies like Baxter International, Fresenius Medical Care, or Nikkiso Co. Ltd. in the dialysis or medical device space.

Corporate Governance

Related Party Transactions

• The RSU grant of 8,983 shares to Patrick T. Hackett, a director of Outset Medical, constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, the eventual vesting and conversion of RSUs into common stock will result in minor dilution.
• Director (Patrick T. Hackett): Receives equity compensation, aligning his financial interests with the company's performance.

Next Steps

• Vesting of the 8,983 Restricted Stock Units upon the earlier of June 2, 2026, or the date of Outset Medical's next Annual Meeting of Stockholders.

Key Dates

Keywords

Outset Medical, OM, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Stock Ownership, Equity Compensation, Reverse Stock Split